Back to Agenda
Abstract Presentations
Session Chair(s)
Philip T. Sager, MD
Adjunct Professor
Stanford University, United States
Speaker(s)
What Can be Done to Enhance Non-Clinical CV Safety Assessment of New Anti-Diabetic Drugs on top of Routine Safety Pharmacology Studies
Nick Edmunds, PhD
Pfizer Global Research and Development, United Kingdom
Cardovascular Discipline Leader, Global Safety Pharmacology
Value of Echocardiography for Diabetic Studies
Nelson Schiller, MD, FACC
Philips BioTel Research, United States
Senior Scientist
Have an account?